Cell division and apoptosis are key aspects of cancer biology. Cdk (cyclin-dependent kinase) associates with cyclins to form Cdk-cyclin complexes, which play a crucial role in cell cycle progression. ​

Breast cancer models are important systems for analyzing Cdk-cyclin complex markers and are highly relevant for understanding tumor heterogeneity.

The Cdk-cyclin complexes regulate a series of events that lead cells from a resting state (G0), the growth phase (G1), through DNA replication (S), and finally to cell division (M). Abnormalities in cell cycle control that occur in any phase lead to cell cycle arrest and might be associated with cancer.

Human cells and cell culture are standard experimental systems for studying Cdk-cyclin complexes and cell cycle regulation. Techniques such as flow cytometry and live cell imaging are key for analyzing cell cycle progression and Cdk-cyclin complex activity. In addition, gene expression analysis and the identification of differentially expressed genes are crucial for understanding Cdk-cyclin complex markers in cancer research.

This guide recommends the most suitable antibodies to study Cdk-cyclin and its regulators in cell cycle progression and cancer.

Introduction to cell cycle

The cell cycle is a fundamental process that governs how cells grow, replicate their DNA, and divide into new cells. This tightly regulated sequence of events ensures that genetic material is accurately copied and distributed, maintaining the health and function of tissues in multicellular organisms. Central to the control of the cell cycle are cyclin-dependent kinases (CDKs) and their regulatory partners, the cyclins. Together, these cyclin-dependent kinases (CDKs) orchestrate the progression through each phase of the cell cycle, responding to internal and external signals. Disruptions in these regulatory mechanisms can lead to uncontrolled cell division, a hallmark of cancer. Understanding the roles of cyclin-dependent kinases CDKs in cell cycle regulation is essential for unraveling the complexities of cell proliferation and the development of cancer therapies.

Cdk-cyclin complexes

Cdk-cyclin complexes are the molecular engines that drive the cell cycle forward. Each complex consists of a cyclin-dependent kinase (CDK) bound to a specific cyclin, forming an active unit that phosphorylates target proteins to trigger key cell cycle events. The activity of these cdk cyclin complexes is tightly regulated, with different combinations becoming active at distinct stages of the cell cycle. For instance, the cdk4-cyclin d1 complex is crucial during the G1 phase, preparing the cell for DNA synthesis, while the cdk1-cyclin b1 complex takes over in the G2/M phase to initiate mitosis. The precise timing and assembly of these cdk cyclin complexes ensure orderly cell cycle progression and prevent errors in cell division. Disruption in the formation or regulation of these complexes can lead to cell cycle arrest or uncontrolled proliferation, both of which are implicated in cancer development.

Cancer cell lines and cdk complexes

Cancer cell lines provide valuable models for studying the dysregulation of the cell cycle that characterizes many tumors. In these cell lines, alterations in the expression or activity of cdk cyclin complexes are common, often resulting in unchecked cell proliferation. For example, breast cancer cell lines frequently exhibit elevated levels of cyclin D1 and cdk4, which can drive the cell cycle forward even in the absence of normal growth signals. This overactivity of cdk cyclin complexes contributes to the rapid growth and survival of cancer cells. By analyzing the specific cdk cyclin complexes present in different cancer cell lines, researchers can gain insights into the molecular mechanisms underlying tumor growth and identify potential targets for therapy. Understanding these patterns is especially important for developing treatments that can selectively inhibit proliferation in cancer cells without affecting normal cell lines.

Role in breast cancer

In breast cancer, the regulation of the cell cycle is often disrupted by changes in cdk cyclin complexes. High expression of cyclin D1 and its partner cdk4 is a common feature in many breast cancer samples, driving excessive cell proliferation and contributing to tumor growth. Additionally, the cdk1-cyclin b1 complex may also be overexpressed, further promoting cell division and the progression of the disease. These alterations in cdk cyclin complexes not only fuel the growth of breast cancer cells but also influence how tumors respond to treatment. By targeting the specific cdk cyclin complexes that are active in breast cancer, researchers and clinicians can develop more effective strategies to inhibit tumor growth and improve patient outcomes.

Cell cycle regulation and cancer

The regulation of the cell cycle is a finely tuned process that balances cell proliferation with the need to maintain genomic integrity. In cancer, this balance is often lost due to the dysregulation of cdk cyclin complexes, leading to uncontrolled cell cycle progression and tumor growth. Key players such as cdk4/6 and their associated cyclins are frequently overactive in cancer cells, bypassing normal checkpoints and enabling continuous division. Therapeutic approaches that target these cdk cyclin complexes, such as cdk4/6 inhibitors, have shown promise in inducing cell cycle arrest and reducing tumor growth in various cancer models. By deepening our understanding of cell cycle regulation and the role of cdk cyclin complexes in cancer, we can develop more precise and effective treatments to combat this disease.

p21

p21, also known as p21^WAF1/Cip1, is a cyclin-dependent kinase (CDK) inhibitor that regulates cell cycle progression. It binds to CDK–cyclin complexes, particularly CDK2 and CDK1, reducing their kinase activity and promoting cell cycle arrest. This interaction is often triggered by cellular stress signals, including DNA damage, and is mediated through both p53-dependent and independent pathways. p21 also associates with proliferating cell nuclear antigen (PCNA), influencing DNA replication and repair. Its expression levels serve as indicators of cell cycle regulation and are frequently studied in contexts such as cancer biology, tissue regeneration, and senescence. As a marker, p21 provides insight into cellular proliferation dynamics and checkpoint control mechanisms.

Figure 1. Immunocytochemistry - Anti-p21 antibody [CIP1/823] - BSA and Azide free (ab212247).

Recommended products

MDM2

MDM2 is a well-characterized E3 ubiquitin ligase that negatively regulates p21, a key CDK–cyclin complex inhibitor. By binding directly to p21, MDM2 facilitates its ubiquitination and targets it for proteasome-mediated degradation. This post-translational regulation significantly influences intracellular p21 protein levels, thereby modulating cell cycle progression. When MDM2 activity is elevated, p21 levels decline, promoting CDK–cyclin activity and cell cycle advancement. Conversely, MDM2 inhibition stabilizes p21, leading to cell cycle arrest in response to stress signals. This regulatory axis is particularly relevant in cancer biology, where dysregulation of MDM2 or p21 can alter proliferation dynamics. Understanding the MDM2–p21 interaction provides valuable insight into cell cycle checkpoints, therapeutic resistance, and tumor suppressor pathways.

Figure 2. Flow Cytometry - Anti-MDM2 antibody [2A10] (ab16895).

Recommended products

Cdk2

Cdk 2 is associated with tumor proliferation in multiple cancer types. Cdk2 forms active complexes with various cyclins, and these active complexes are essential for cell cycle progression. Binding of p21 to Cdk2-cyclin E complex arrests cells at the G1/S checkpoint. Different cyclin genes encode the cyclins that partner with Cdk2, contributing to the regulation of the G1/S checkpoint. Cdk2 inhibition by p21 is therefore crucial for DNA damage repair.

Figure 3. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cdk2 antibody [E304] (ab32147).

Recommended products

Cyclin B1

Cyclin B1 is a regulatory protein that partners with cyclin-dependent kinases, primarily CDK1, to control the G2 to M phase transition in the cell cycle. This complex phosphorylates key substrates to initiate mitosis and ensure proper chromosome alignment and segregation. Cyclin B1 accumulates during G2, peaks in mitosis, and is rapidly degraded at anaphase onset. It also forms a functional complex with CDK5, contributing to mitotic fidelity. As a marker, cyclin B1 reflects active cell division and is widely studied in cancer research, drug development, and cell cycle analysis. Its expression and localization patterns offer insights into proliferative states and checkpoint regulation in both normal and transformed cells.

Figure 4. Flow Cytometry (Intracellular) - Anti-Cyclin B1 antibody [Y106] (ab32053).

Recommended products

Cyclin E1

The cyclin E1–CDK2 complex plays a key role in regulating the G1 to S phase transition during the cell cycle. This complex phosphorylates the retinoblastoma protein (Rb), leading to the release of E2F transcription factors that activate genes required for DNA replication. Cyclin E1 levels rise in late G1, coordinating with CDK2 to initiate S phase entry and promote genomic duplication. Dysregulation of cyclin E1 or CDK2 activity is often observed in cancer, where altered cell cycle control contributes to unchecked proliferation. As a marker of CDK–cyclin activity, cyclin E1 is widely studied in cell cycle research, oncology, and drug development. Its expression reflects proliferative status and checkpoint integrity in both normal and transformed cells.

Figure 5. Immunocytochemistry/ Immunofluorescence - Anti-Cyclin E1 antibody [EP435E] (ab33911).

Recommended products

Cdc25c

Cdc25 phosphatases regulate cell cycle progression by activating cyclin-dependent kinases. Specifically, Cdc25 removes inhibitory phosphates from threonine 14 (T14) and tyrosine 15 (Y15) on CDK2, enabling its full activation. This dephosphorylation step is rate-limiting and tightly controlled, ensuring proper timing of S phase entry. Among the Cdc25 family, Cdc25C is particularly important for CDK2 activation during the G2/M transition. Its nuclear localization is key to its function, allowing direct access to CDK2–cyclin complexes. Mislocalization or altered expression of Cdc25C can disrupt cell cycle control and is frequently observed in cancer cells. As a marker of CDK–cyclin activity, Cdc25C provides insight into checkpoint regulation, proliferation status, and potential therapeutic targets.

Figure 6. Western blot - Anti-Cdc25C antibody [E302] (ab32444).

Recommended products

CDC6

CDC6 is a key regulator of DNA replication initiation in eukaryotic cells. It functions by assembling the pre-replicative complex at origins of replication during the G1 phase, preparing the cell for S phase entry. CDC6 protein expression increases in G1 and is stabilized by CDK2–cyclin E activity, linking its regulation to cell cycle progression. Beyond its replication role, CDC6 has been associated with oncogenic activity in various cancers, where its overexpression can disrupt checkpoint control and promote genomic instability. Studies in developmental biology and gene regulation have highlighted CDC6’s involvement in cell cycle dynamics and its potential as a biomarker for proliferative states. Its dual role in replication and transformation makes it a subject of interest in cancer research and therapeutic development.

Figure 7. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cdc6 antibody [EPR714(2)] (ab109315).

Recommended products

Cdk4/6 and Cyclin D1/2

The cyclin D–CDK4/6 complex is a key regulator of the G1 phase of the cell cycle. CDK4 and CDK6, when bound to cyclin D isoforms, phosphorylate the retinoblastoma protein (Rb), promoting E2F release and progression toward S phase. This kinase activity is tightly regulated and inhibited by CDK inhibitors such as p21, which binds the complex and reduces its activity. In the absence of CDK4 and CDK6, cyclin D2 can associate with CDK2, forming alternative complexes that support cell cycle progression. Dysregulation of these pathways is frequently observed in tumor cells, where overactive cyclin–CDK signaling contributes to uncontrolled proliferation. These complexes are widely studied as biomarkers and therapeutic targets in oncology and cell cycle research.

Figure 8. Immunocytochemistry/ Immunofluorescence - Anti-Cdk4 antibody [EPR4513-32-7] (ab108357).

Recommended products

Retinoblastoma protein

The retinoblastoma protein (Rb) is a key regulator of the G1 to S phase transition in the cell cycle. It becomes inactivated through phosphorylation by CDK4/6 and CDK2, allowing the release of E2F transcription factors that drive the expression of genes required for DNA replication. When CDK activity is inhibited by proteins such as p21, Rb remains in a hypophosphorylated, active state. In this form, Rb binds to E2F and suppresses transcription, effectively halting cell cycle progression. Changes in Rb phosphorylation status can be monitored using flow cytometry, which enables researchers to assess cell cycle distribution and identify shifts in G1, S, and G2/M phases. This makes Rb a valuable marker in studies of proliferation and checkpoint regulation.

Figure 9. Western blot - Anti-Retinoblastoma binding protein 6 antibody (ab237514).

Recommended products

References

1. Harper, J.W.  et al.  Inhibition of cyclin-dependent kinases by p21.  Mol. Biol. Cell  6, 387–400 (1995).

2. Charrier-Savournin, F.B.  et al.  p21-mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress.  Mol. Biol. Cell  15, 3965–3976 (2004).

3. Zhang, Z. et al. MDM2 is a negative regulator of p21^WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000–16006 (2004).

4. O’Connor, P.M. Mammalian G1 and G2 phase checkpoints.  Cancer Surv.  29, 151–182 (1997).

5. Pines, J. & Hunter, T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34^cdc2^.  Cell  58, 833–846 (1989).

6. Boutros, R., Dozier, C. & Ducommun, B. The when and wheres of CDC25 phosphatases.  Curr. Opin. Cell Biol.  18, 185–191 (2006).

7. Dimova, D.K. & Dyson, N.J. The E2F transcriptional network: old acquaintances with new faces.  Oncogene  24, 2810–2826 (2005).

8. Donzelli, M. & Draetta, G.F. Regulating mammalian checkpoints through Cdc25 inactivation.  EMBO Rep.  4, 671–677 (2003).

9. Sideridou, M., Zakopoulou, R. & Gorgoulis, V.G. Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins.  J. Cell Biol.  195, 1123–1140 (2011).

10. Duursma, A.M. & Agami, R. CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication.  Cell Cycle  4, 1725–1728 (2005).

11. Cole, A.M.  et al.  Cyclin D2–cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss.  Cancer Res.  70, 8149–8158 (2010).

12. Baker, S.J. & Reddy, E.P. CDK4: a key player in the cell cycle, development, and cancer.  Genes Cancer  3, 658–669 (2012).

13. Münger, K. & Howley, P.M. Human papillomavirus immortalization and transformation functions.  Virus Res.  89, 213–228 (2002).